VANCOUVER, BC / ACCESSWIRE / September 28, 2017 / Canadian Zeolite Corp. (the “Company”) (TSX-V: CNZ) (OTCQB: CNZCF) (FSE: ZEON) an international marketer and distributor of zeolite and zeolite products is pleased to announce the appointment of Mr. Larry Brandenburg to the Advisory Board to oversee business development and strategic planning as the Company continues to establish its operations in Canada and develop an international sales strategy.

Mr. Brandenburg brings over 40 years experience in the oil sands and oil distribution industry as the CEO of a private consulting company. He has been involved in oil sand expansion projects, water remediation and has expertise in field management, field supervision, turnaround co-ordination, planning, scheduling and design. He has been instrumental in planning and managing operations for projects both domestically and in international markets.

Mr. Brandenburg stated, “I am pleased to be joining a company that has multiple opportunities within the large and dynamic industries of food production, green house gas reduction and water filtration. Zeolite is a green-tech product that is used extensively in other parts of the world within these industries and is now gaining awareness and momentum in the North American market. We will remain focused on developing the industries we have already penetrated and with the positive cash flows that are generated fund our international expansion opportunities.”

Mr. Ray Paquette, CEO of Canadian Zeolite stated, “Mr. Brandenburg’s expertise and experience will give us the needed support through this growth stage. We continue to qualify new distributors and are expanding our current product line. We are seeing very positive results in our research and development and will publish results as ready.”

On behalf of the Board of Directors

“Ray Paquette”

President & CEO
604.684.3301
www.canadianzeolite.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward-looking information. These statements include, but are not limited to, statements with respect to future expenditures. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the ability to complete contemplated work programs and the timing and amount of expenditures. Canadian Zeolite does not assume the obligation to update any forward-looking statement.

SOURCE: Canadian Zeolite Corp.

ReleaseID: 476514

BOCA RATON, FL / ACCESSWIRE / September 28, 2017 / Bright Mountain Media, Inc. (www.brightmountainmedia.com) (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a digital media holding company for online assets primarily targeted to the military and public safety sectors, today is pleased to announce that on September 19, 2017, and pursuant to the terms of an Amended and Restated Purchase Agreement (“Agreement”) by and among the Company, Daily Engage Media Group LLC (“Daily Engage”) and its members, Harry G. Pagoulatos, George G. Rezitis and Angelos Triantafillou acquired 100% of the membership interests of Daily Engage.

Launched in 2015, Daily Engage is an ad network that connects advertisers with approximately 200 digital publications worldwide. Daily Engage’s revenues for the year ended December 31, 2016 (audited) were $1,6747,596 and it reported a net loss of $33,607. Following the closing of the transaction, and subject to the availability of additional working capital, we expect to complete the development of the ad exchange platform Daily Engage has under development.

The consideration for the acquisition of Daily Engage was as follows:

$380,000 paid through the delivery of unsecured, interest-free, one-year promissory notes (the “Closing Notes”);
An aggregate of 1,100,223 shares of our common stock valued at $429,087 (“Consideration Shares”);
The forgiveness of $204,411.08 in working capital we had previously advanced Daily Engage; and
Satisfaction of $108,620 due by Daily Engage Media to various lenders.

Under the terms of the Agreement, upon Daily Engage achieving certain revenue and operating income targets, we agreed to issue additional consideration as follows:

If Daily Engage’s revenues are at least $20,228,954, and it has operating income of at least $3,518,623 during the first 12 months following the closing date, we agreed to pay an additional $500,000 in cash and issue an additional 1,008,547 shares of our common stock;
If Daily Engage’s revenues are at least $60,385,952, and operating income of at least $11,380,396 during the first 12 months following the Year-One Earnout Period, we agreed to pay an additional $500,000 in cash and issue an additional 796,221 shares of our common stock; and
If Daily Engage’s revenues are at least $96,512,204, and it has operating income of at least $18,524,967 during the 12 months following the Year-Two Earnout Period, we agreed to pay an additional $500,000 in cash and issue an additional 723,523 shares of our common stock.

To the extent the targets are not met in any particular earnout period, but are cumulatively obtained in subsequent earnout periods, they will be entitled to the additional consideration for those earlier periods.

On the closing date of the acquisition of Daily Engage, we entered into three-year employment agreements with Messrs. Harry G. Pagoulatos and George G. Rezitis, two of the members. Mr. Pagoulatos and Mr. Rezitis will serve as Chief Operating Officer and Chief Technology Officer, respectively, of our Daily Engage Media Group.

In commenting on the acquisition Mr. W. Kip Speyer, Chairman and President of the Company stated, “The acquisition of Daily Engage is a key component to the development and commercialization of our ad exchange platform and should, with additional working capital, provide impetus for the associated future growth of our company.” Commenting further, Mr. Speyer said that, “I am thrilled that Harry G. Pagoulatos and George G. Rezitis have elected to stay with the company as key members of its management team.”

Messrs. Pagoulatos and Rezitis have stated, “That they look forward to working with Kip and the other members of the Bright Mountain team and believe that the combination of the two companies will be very exciting.”

The Company has filed a Current Report on Form 8-K filed on September 25, 2017 with the Securities and Exchange Commission which contains additional details on this transaction. To view the report, please visit the Securities and Exchange Commission website at www.sec.gov.

About Bright Mountain Media

Bright Mountain Media, Inc. (BMTM) is an owner, acquirer, and manager of customized websites for military and public safety audiences. We are dedicated to providing “those that keep us safe” places to go online where they can do everything from staying current on news and events affecting them to look for jobs, share information, communicate with the public and more. For more information, please visit us at https://www.brightmountainmedia.com/.

Safe Harbor Statement

This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results or implied by such statements. Bright Mountain Media, Inc.’s future results may also be impacted by other risk factors listed from time-to-time in its SEC filings including, but are not limited to, our ability to raise sufficient working capital to pay our obligations as they become due and fund its growth initiatives, our history of losses and ability to continue as a going concern, the possible failure to transition to a primarily advertising-based revenue model, our dependence on our relationships with Google AdSense, Amazon and eBay, risks associated with integration of acquired websites, failure to protect our content and possible inadvertent infringement of third party intellectual property rights, our ability to effectively compete, our acquisition strategy, and a limited public market for our common stock, among other risks and uncertainties, all as set forth in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission, and our subsequent filings with the SEC. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made and Bright Mountain Media, Inc. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Investor Relations:

www.brightmountainmedia.com/investor-relations

SOURCE: Bright Mountain Media, Inc.

ReleaseID: 476493

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / CV Sciences, Inc. (OTCQB: CVSI) (the ”Company,” ”CV Sciences,” ”our,” or ”we”), market-leading supplier and manufacturer of hemp-derived cannabidiol (CBD) products and developer of specialty pharmaceutical therapeutics, will be presenting at this year’s MicroCap Conference on October 5th in New York City.

Joseph Dowling, Chief Financial Officer of CV Sciences, Inc. will be delivering a presentation to attendees providing details about its lead drug candidate, CVSI-007, which utilizes synthetically-formulated CBD for the treatment of smokeless tobacco addiction. In addition, Mr. Dowling will discuss the Company’s success within its consumer CBD products division, review recent Company highlights and be available for one-on-one meetings. To arrange a one-on-one meeting with management, please contact Robert Haag at CVSI@irthcommunications.com or 866-976-4784.

Please use the following link for the Webcast: http://wsw.com/webcast/microcapconf5/cvsi/

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday at 7:00AM, and will last until the evening. The Conference will be jam-packed with company sessions, presentations, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please visit The MicroCap Conference website (microcapconf.com/conferences/new-york-2-2017/), and click ”Investor Registration.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to The MicroCap Conference website (microcapconf.com/conferences/new-york-2-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

OTHER SPONSORS

M2 Compliance
MZ Group
Pryor Cashman
Wexler Burkhart Hirschberg & Unger
IRTH Communications
PCG Advisory Group
CORE IR
Catalyst IR
Marcum

About CV Sciences, Inc.

CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Contact:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com

SOURCE: CV Sciences, Inc.

ReleaseID: 476484

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Siyata Mobile Inc. (TSX-V: SIM; OTCQX: SYATF) will be presenting at this year’s MicroCap Conference on October 5th in New York City.

Marc Seelenfreund, CEO and Chairman of Siyata Mobile, commented, “We are very pleased to present our story at the MicroCap Conference, a leading microcap event where the core investors are U.S. based. With Siyata in its early stages of a large-scale U.S. rollout potential, we believe that our story will be of great interest to the U.S. investor community.”

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on October 5th. Registration will begin on Thursday at 7:00AM, and will last until the evening. These days will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (microcapconf.com/conferences/new-york-2-2017/), and click “Investor Registration.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (microcapconf.com/conferences/new-york-2-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

OTHER SPONSORS

M2 Compliance
MZ Group
Pryor Cashman
Wexler Burkhart Hirschberg & Unger
IRTH Communications
PCG Advisory Group
CORE IR
Catalyst IR
Marcum

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

SOURCE: Siyata Mobile Inc.

ReleaseID: 476240

DENVER, CO / ACCESSWIRE / September 28, 2017 / Medicine Man Technologies Inc. (OTCQB: MDCL), (“Medicine Man” or “the Company”), one of the United States’ leading cannabis branding and consulting companies, is pleased to announce it will host a company presentation at this year’s MicroCap Conference on Thursday, October 5th in New York City. Furthermore, members of the management team will participate on a panel discussion at the conference related to cannabis investing.

The company presentation will be held at 11:00 AM Eastern Time on Track 5 and will be broadcast live over the Company’s website and at http://wsw.com/webcast/microcapconf5/mdcl/. The panel, titled “The Latest in Cannabis Investing”, will be held at 5:40 PM Eastern Time on the same day, Thursday October 5th, and will be moderated by Brett Roper, Medicine Man’s Chief Executive Officer, with Josh Haupt, the Company’s Chief Cultivation Officer, participating as a panelist.

“Our technology and consulting solutions optimize both the yields and quality of our clients’ cannabis products, helping to improve their business performance, and ultimately maximize their profits,” commented Brett Roper, Chief Executive Officer of Medicine Man. “As the cannabis industry gains momentum and the number of new market entrants continues to expand, Medicine Man is experiencing increasing demand for its services. Attending industry conferences, such as the MicroCap conference, enables us to raise the Company’s profile across the investment community as we execute on our aggressive growth strategy, driven by our recent acquisitions of Pono Publications, Success Nutrients and Denver Consulting Group.”

To be added to the distribution list, please email MDCL@kcsa.com with “MDCL” in the subject line.

About the MicroCap Conference

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors. The event will be jam-packed with company sessions, presentations, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

To register, please go to our website www.microcapconf.com and click “Investor Registration”. Or, contact Tony Yu at tony@microcapconf.com

About Medicine Man Technologies, Inc.

Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. It currently has twenty eight active clients in 12 states and Puerto Rico, focusing on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company’s highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will ‘share’ the ever-improving experience and knowledge of the network, and 5) continuing the expansion of its Brands Warehouse concept.

News Compliments of ACCESSWIRE.

Contact Information:

KCSA Strategic Communications
MDCL@kcsa.com

SOURCE: Medicine Man Technologies Inc.

ReleaseID: 476509

BEDMINSTER, NJ / ACCESSWIRE / September 28, 2017 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that Chief Executive Officer, Khoso Baluch, will present at The MicroCap Conference, to be held October 5, 2017, at The Essex House in New York City. CorMedix’s presentation is scheduled for 2pm Eastern Time in Track 1.

Mr. Baluch will provide an overview of the company’s business during a live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product, Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit: www.cormedix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to possible uses of taurolidine, that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the possible inability to capture sufficient CRBSI events in the ongoing Phase 3 clinical trial for Neutrolin® even with the reported changes to that trial; the cost, timing and results of the ongoing and planned Phase 3 trials for Neutrolin® in the U.S. and the resources needed to commence and complete those trials; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources and the impact on planned or future research, including for additional uses for taurolidine; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations; preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials; and the ability to retain and hire necessary personnel to staff our operations appropriately. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

For Investors & Media:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

SOURCE: CorMedix Inc.

ReleaseID: 476113

NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Vail Resorts, Inc. (NYSE: MTN) will be discussing their earnings results in their Q4 Earnings Call to be held September 28, 2017 at 11:30 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/1212.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/1212.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 476569

LONDON, UK / ACCESSWIRE / September 28, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on John Wiley & Sons, Inc. (NYSE: JW-A), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=JW-A, following the Company’s reporting of its first quarter fiscal 2018 (Q1 FY18) earnings results on September 07, 2017. The Hoboken, New Jersey-based Company’s revenue and adjusted EPS grew 2% and 9% y-o-y, respectively, beating market consensus estimates. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on JW-A. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=JW-A

Earnings Reviewed

For Q1 FY18, John Wiley & Sons’ revenue came in at $411.44 million, rising from $404.29 million in Q1 FY17. The revenue figures topped market expectations of approximately $400 million. Furthermore, the Company’s revenue grew 1% y-o-y on a constant currency basis in Q1 FY18.

The book and journal publisher reported GAAP net income of $9.24 million, or $0.16 per diluted share, in Q1 FY18 compared to $31.01 million, or $0.53 per diluted share, in the prior year’s corresponding quarter. Meanwhile, the Company’s adjusted net income increased to $33.96 million, or $0.59 per diluted share, for the reported quarter from $31.49 million, or $0.54 per diluted share, in the last year’s comparable quarter, beating market consensus estimates of $0.53 per diluted share.

Operating Metrics

In Q1 FY18, John Wiley & Sons’ cost of sales were $114.79 million compared to $113.48 million in the last year’s same quarter. The Company’s adjusted operating and administrative expenses came in at $240.21 million during Q1 FY18 compared to $235.34 million in Q1 FY17. Additionally, adjusted total costs and expenses were $367.62 million for Q1 FY18 versus $361.39 million in the prior year’s comparable quarter.

During the reported quarter, GAAP operating income fell to $14.50 million, or 3.5% of revenues, from $43.81 million, or 10.8% of revenues, in Q1 FY17. Meanwhile, adjusted operating income improved to $43.83 million, or 10.7% of revenues, during Q1 FY18 from $42.89 million, or 10.6% of revenues, in the previous year’s corresponding quarter.

Segment-Wise

In Q1 FY18, John Wiley & Sons’ Research segment’s revenue increased 8% to $223.63 million from $207.22 million in Q1 FY17. In Q1 FY18, the segment’s adjusted profit also increased to $66.30 million from $60.37 million in Q1 FY17.

The Company’s Publishing segment’s revenue fell 9% to $131.28 million y-o-y on a GAAP basis in Q1FY18, while it was also down by 8% on a constant currency basis. Furthermore, the segment’s adjusted profit contribution declined to $15.86 million in Q1 FY18 from $19.67 million in the last year’s comparable quarter.

In Q1 FY18, John Wiley & Sons’ Solutions segment’s revenue rose 9% to $56.54 million on both GAAP and constant currency basis from $52.10 million in Q1 FY17. Meanwhile, the segment’s adjusted profit increased to $0.83 million in Q1 FY18 from $0.15 million in Q1 FY17.

Balance Sheet

In the three months ended July 31, 2017, John Wiley & Sons’ net cash used in operating activities totaled $81.83 million compared to net cash used in operating activities of $136.71 million in the previous year’s same period. Furthermore, the Company reported negative free cash flow less product development spending of $117.85 million in Q1 FY18 compared to negative free cash flow less product development spending of $165.48 million in the prior year’s corresponding period.

As on July 31, 2017, the Company had $84.11 million in cash and cash equivalents compared to a balance of $185.89 million as on July 31, 2016. Additionally, the Company reported a long-term debt of $551.65 million in its books of accounts as on July 31, 2017, compared to $653.00 million as on July 31, 2016.

Share Repurchases

During Q1 FY18, John Wiley & Sons’ repurchased 265,158 shares at an average cost of $52.86 per share for a total of $14 million. The Company had a balance of over 3.5 million shares under its stock repurchase authorization at the end of Q1 FY18.

Earnings Outlook

John Wiley & Sons’ management reaffirmed the Company’s outlook for the full year FY18 and expects total revenue growth to be approximately even with a low single-digit decline in adjusted EPS, excluding foreign exchange.

Stock Performance

John Wiley & Sons’ share price finished yesterday’s trading session at $53.50, marginally sliding 0.09%. A total volume of 338.85 thousand shares have exchanged hands, which was higher than the 3-month average volume of 169.32 thousand shares. The Company’s stock price advanced 0.56% in the last one month, 0.38% in the past six months, and 7.24% in the previous twelve months. Shares of the Company have a PE ratio of 33.82 and have a dividend yield of 2.39%. The stock currently has a market cap of $3.03 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 476550

LONDON, UK / ACCESSWIRE / September 28, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Moleculin Biotech, Inc. (NASDAQ: MBRX) (“Moleculin”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MBRX. The Houston based preclinical and clinical-stage pharmaceutical Company announced on September 26, 2017, that it has received approval from the Food and Drug Administration (FDA) to start clinical trials of Annamycin in the treatment of relapsed or refractory Acute Myeloid Leukemia (AML). The approval was granted after FDA completed its safety review of information and a proposed protocol submitted by Moleculin in an Investigational New Drug application (IND). For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MBRX. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=MBRX

The US IND also allowed Moleculin to make a submission to Polish authorities for the planned Annamycin clinical trial to be conducted in Poland.

FDA Approval Represents a Tremendous Milestone for Moleculin

Walter Klemp, Chairman and CEO of Moleculin, stated that this represents a tremendous milestone for Moleculin. The Company’s primary focus has been to get Annamycin back into the clinic so it can begin optimizing the dosing of the drug as the next step in evaluating its potential to become the first 2nd line therapy suitable for the majority of relapsed or refractory AML patients.

Moleculin Adopted Additional Patient Safeguards to be Implemented while Establishing Recommended Phase-2 Dose

Dr. Robert Shepard, Moleculin’s Chief Medical Officer, mentioned that the Company has adopted additional patient safeguards that will be implemented while it seeks to establish the Recommended Phase-2 Dose. This will include reporting interim safety data to FDA before allowing US patients to progress beyond initial agreed-upon dosing limits. Dr. Robert added that after seeing indications of what Annamycin may be capable of from earlier clinical trials, he made it a career goal to get the drug back into the proper clinical trials to determine its potential.

Moleculin Filed IND with FDA for Annamycin in August 2017

News release suggests that on August 08, 2017, Moleculin filed with the FDA an Investigational New Drug application to study Annamycin in the treatment of relapsed or refractory AML. The purpose of the filing was to seek approval for treating AML.

Moleculin previously filed an IND, in response to which the FDA requested certain revisions to the protocol, additional information, and additional data related to Chemistry, Manufacturing, and Controls (CMC). The Company withdrew its original application to incorporate the request, with the goal of resubmitting the application when that was accomplished.

About Annamycin

Annamycin is an anthracycline antibiotic intended for the treatment of relapsed or refractory AML. Annamycin is classified as a member of the anthracycline family and has been engineered to be non-cardiotoxic and invisible to the body’s natural defense mechanisms. The drug is Moleculin’s lead product candidate. In the two most recent trials, Annamycin was able to generate significant activity with acute leukemia patients who would be considered part of the unlucky 80% or labeled as untreatable.

About Moleculin Biotech Inc.

Founded in 2015, Moleculin Biotech, Inc. is focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center, the world’s largest cancer research facility.

Last Close Stock Review

On Wednesday, September 27, 2017, the stock closed the trading session at $2.50, declining 6.02% from its previous closing price of $2.66. A total volume of 989.40 thousand shares have exchanged hands. Moleculin Biotech’s stock price skyrocketed 6.84% in the last one month and 125.20% in the previous six months. Furthermore, since the start of the year, shares of the Company have surged 9.65%. The stock currently has a market cap of $51.10 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 476553

LONDON, UK / ACCESSWIRE / September 28, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Malibu Boats, Inc. (NASDAQ: MBUU) (“Malibu”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=MBUU, following the Company’s disclosure of its financial results on September 07, 2017, for the fourth quarter of the fiscal year 2017. The Company’s revenue increased 12.6% on a y-o-y basis. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MBUU. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=MBUU

Earnings Reviewed

For the three months ended June 30, 2017, Malibu’s revenue increased 12.6% to $75.11 million from $66.68 million in Q4 FY16. The revenue surpassed analysts’ expectations of $74.0 million.

During Q4 FY17, Malibu’s gross profit increased 12.3% to $20.04 million from $17.83 million in Q4 FY16. For the reported quarter, the Company’s gross margin was at par with the 26.6% of revenue in Q4 FY16.

For the reported quarter, the Company’s adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) increased 14.3% to $15.46 million from $13.52 million in Q4 FY16. During Q4 FY17, Malibu’s adjusted EBITDA margin increased 30 basis points to 20.6% of revenue from 20.3% of revenue in Q4 FY16.

For the reported quarter, Malibu’s S&M expenses increased 52.7% to $2.26 million from $1.48 million in Q4 FY16. The increase was primarily due to the timing of annual photo shoot and various marketing initiatives. During Q4 FY17, the Company’s amortization expenses increased 18 basis points to $549,000 from $548,000 in Q4 FY16. For the reported quarter, the Company’s G&A expenses increased 16.1% to $9.27 million from $7.98 million in Q4 FY16.

During Q4 FY17, Malibu’s operating income increased 1.7% to $7.97 million from $7.83 million in Q4 FY16. For the reported quarter, the Company’s operating margin decreased 110 basis points to 10.6% of revenue from 11.7% of revenue in Q4 FY16.

During Q4 FY17, Malibu’s net income increased 168.3% to $9.66 million on a y-o-y basis from $3.60 million in Q4 FY16. For the reported quarter, the Company’s adjusted net income increased 12.8% to $8.23 million on a y-o-y basis from $7.29 million in Q4 FY16. During Q4 FY17, Malibu’s diluted earnings per share (EPS) increased 165% to $0.53 on a y-o-y basis from $0.20 in Q4 FY16. For the reported quarter, the Company’s adjusted diluted EPS increased 13.1% to $0.43 on a y-o-y basis from $0.38 in Q4 FY16. The adjusted diluted EPS surpassed analysts’ expectations of $0.42.

In July 2017, the Company completed the acquisition of Cobalt Boats.

Balance Sheet

As on June 30, 2017, Malibu’s cash increased 26.6% to $32.82 million from $25.92 million in Q4 FY16.

During Q4 FY17, the Company’s net trade receivable decreased 32.9% to $9.85 million from $14.69 million in Q4 FY16.

During Q4 FY17, Malibu’s net inventories increased 16.6% to $23.84 million from $20.43 million in Q4 FY16.

For the reported quarter, the Company’s accounts payable decreased 21.2% to $12.72 million from $16.16 million in Q4 FY16.

Outlook

For FY17, Malibu expects net revenue per unit to increase in the low- to mid-single digits and gross margin to be 24% of revenue. The Company estimates adjusted EBITDA margin to be more than 17% of revenue and capital expenditures to be in the range of $13 million – $14 million for the fiscal year 2017.

Stock Performance

At the closing bell, on Wednesday, September 27, 2017, Malibu Boats’ stock climbed 2.18%, ending the trading session at $30.89. A total volume of 219.97 thousand shares have exchanged hands. The Company’s stock price skyrocketed 19.96% in the last three months, 38.27% in the past six months, and 102.56% in the previous twelve months. Moreover, the stock soared 61.90% since the start of the year. The stock is trading at a PE ratio of 19.58 and currently has a market cap of $622.74 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 476551